| CUTOMETER® MEASUREMENTS | |||||
| Firmness (R0 → Uf) | |||||
|
| Variations Δ | ||||
| Sub# | D0 | D28 | D56 | D28 | D56 |
| 1 | 0.249 | 0.180 | 0.291 | −0.070 | 0.042 |
| 2 | 0.382 | 0.290 | 0.252 | −0.092 | −0.130 |
| 3 | 0.275 | 0.250 | 0.250 | −0.026 | −0.026 |
| 4 | 0.318 | 0.261 | 0.296 | −0.057 | −0.022 |
| (5)* | (0.350) * AV | (0.293) * AV | (0.295) * AV | (−0.058) * AV | (−0.055) * AV |
| 6 | 0.465 | 0.308 | 0.178 | −0.157 | −0.287 |
| 7 | 0.421 | 0.325 | 0.305 | −0.096 | −0.116 |
| 8 | 0.297 | 0.233 | 0.221 | −0.065 | −0.077 |
| 9 | 0.301 | 0.247 | 0.254 | −0.054 | −0.047 |
| 10 | 0.321 | 0.271 | 0.171 | −0.050 | −0.150 |
| 11 | 0.336 | 0.308 | 0.235 | −0.028 | −0.101 |
| (12)* | (0.288) * AV | (0.244) * AV | (0.159) * AV | (−0.044) * AV | (−0.129) * AV |
| 13 | 0.467 | 0.450 | 0.390 | −0.017 | −0.077 |
| 14 | 0.397 | 0.369 | 0.347 | −0.028 | −0.051 |
| 15 | 0.436 | 0.390 | UN | −0.047 | UN |
| 16 | 0.352 | 0.316 | 0.257 | −0.036 | −0.095 |
| 17 | 0.342 | 0.339 | 0.323 | −0.003 | −0.019 |
| 18 | 0.420 | 0.377 | 0.345 | −0.043 | −0.075 |
| 19 | 0.531 | 0.488 | 0.457 | −0.043 | −0.075 |
| 20 | 0.295 | NC | 0.280 | NC | −0.015 |
| 21 | 0.344 | 0.324 | 0.319 | −0.021 | −0.025 |
| 22 | 0.359 | 0.316 | 0.298 | −0.044 | −0.061 |
| Mean | 0.365 | 0.318 | 0.288 | −0.051 | −0.074 |
| Med | 0.348 | 0.316 | 0.291 | −0.044 | −0.075 |
| Min | 0.249 | 0.180 | 0.171 | −0.157 | −0.287 |
| Max | 0.531 | 0.488 | 0.457 | −0.003 | 0.042 |
| SEM | 0.016 | 0.017 | 0.016 | 0.008 | 0.016 |
| 95% CI | 0.034 | 0.036 | 0.033 | 0.017 | 0.033 |
| # of subjects | 20 | 19 | 19 | 19 | 19 |
| Δ % | −13% | −21% | |||
| % of cutaneous firmness improvement: firming effect (-R0) | +13% | +21% | |||
| Statistical analysis p = | <0.001 | <0.001 | |||
| Statistical test | T-test | T-test | |||
| % of subjects with an improvement in the cutaneous firmness (NB: if variation < −0.01) | 95% | 95% | |||
| Suppleness Ue | |||||
|
| Variations Δ | ||||
| Sub# | D0 | D28 | D56 | D28 | D56 |
| 1 | 0.179 | 0.124 | 0.213 | −0.055 | 0.034 |
| 2 | 0.280 | 0.232 | 0.186 | −0.048 | −0.094 |
| 3 | 0.181 | 0.170 | 0.172 | −0.011 | −0.009 |
| 4 | 0.224 | 0.166 | 0.214 | −0.059 | −0.010 |
| (5)* | (0.286) * AV | (0.219) * AV | (0.207) * AV | (−0.068) * AV | (−0.079) * AV |
| 6 | 0.350 | 0.213 | 0.118 | −0.138 | −0.232 |
| 7 | 0.308 | 0.247 | 0.210 | −0.061 | −0.098 |
| 8 | 0.209 | 0.167 | 0.156 | −0.043 | −0.053 |
| 9 | 0.227 | 0.175 | 0.185 | −0.052 | −0.042 |
| 10 | 0.241 | 0.194 | 0.111 | −0.047 | −0.130 |
| 11 | 0.258 | 0.220 | 0.179 | −0.038 | −0.079 |
| (12)* | (0.216) * AV | (−0.164) * AV | (0.123) * AV | (−0.053) * AV | (−0.093) * AV |
| 13 | 0.354 | 0.396 | 0.340 | 0.042 | −0.014 |
| 14 | 0.306 | 0.320 | 0.298 | 0.014 | −0.008 |
| 15 | 0.355 | 0.340 | UN | −0.016 | UN |
| 16 | 0.258 | 0.227 | 0.211 | −0.031 | −0.047 |
| 17 | 0.304 | 0.296 | 0.278 | −0.008 | −0.027 |
| 18 | 0.341 | 0.322 | 0.293 | −0.019 | −0.048 |
| 19 | 0.391 | 0.427 | 0.414 | 0.037 | 0.023 |
| 20 | 0.242 | NC | 0.229 | NC | −0.013 |
| 21 | 0.293 | 0.243 | 0.253 | −0.051 | −0.041 |
| 22 | 0.310 | 0.266 | 0.234 | −0.045 | −0.076 |
| Mean | 0.280 | 0.249 | 0.226 | −0.033 | −0.051 |
| Med | 0.286 | 0.232 | 0.213 | −0.043 | −0.042 |
| Min | 0.179 | 0.124 | 0.111 | −0.138 | −0.232 |
| Max | 0.391 | 0.427 | 0.414 | 0.042 | 0.034 |
| SEM | 0.014 | 0.019 | 0.017 | 0.009 | 0.014 |
| 95% CI | 0.028 | 0.040 | 0.036 | 0.019 | 0.029 |
| # of subjects | 20 | 19 | 19 | 19 | 19 |
| Δ % | −11% | −19% | |||
| % of cutaneous suppleness improvement (Ue) | −11% | −19% | |||
| Statistical analysis p = | 0.001* | 0.002* | |||
| Statistical test | T-test | T-test | |||
| % of subjects with an improvement in the cutaneous suppleness (NB: if variation> 0.01) *not clinically relevant | 16% | 11% | |||
| Tonicity Ur | |||||
|
| Variations Δ | ||||
| Sub# | D0 | D28 | D56 | D28 | D56 |
| 1 | 0.056 | 0.089 | 0.096 | 0.033 | 0.040 |
| 2 | 0.110 | 0.115 | 0.096 | 0.006 | −0.014 |
| 3 | 0.075 | 0.092 | 0.106 | 0.017 | 0.031 |
| 4 | 0.093 | 0.070 | 0.096 | −0.023 | 0.004 |
| (5)* | (0.229) * AV | (0.135) * AV | (0.140) * AV | (−0.095) * AV | (−0.089) * AV |
| 6 | 0.159 | 0.133 | 0.150 | −0.027 | −0.009 |
| 7 | 0.104 | 0.117 | 0.132 | 0.014 | 0.028 |
| 8 | 0.093 | 0.088 | 0.097 | −0.006 | 0.004 |
| 9 | 0.141 | 0.085 | 0.078 | −0.056 | −0.063 |
| 10 | 0.077 | 0.104 | 0.088 | 0.027 | 0.011 |
| 11 | 0.159 | 0.212 | 0.128 | 0.053 | −0.031 |
| (12)* | (0.161) * AV | (0.089) * AV | (0.053) * AV | (−0.073) * AV | (−0.108) * AV |
| 13 | 0.204 | 0.213 | 0.158 | 0.009 | −0.046 |
| 14 | 0.149 | 0.160 | 0.192 | 0.011 | 0.044 |
| 15 | 0.274 | 0.290 | UN | 0.016 | UN |
| 16 | 0.111 | 0.115 | 0.142 | 0.004 | 0.031 |
| 17 | 0.125 | 0.120 | 0.135 | −0.005 | 0.010 |
| 18 | 0.217 | 0.244 | 0.191 | 0.028 | −0.026 |
| 19 | 0.152 | 0.164 | 0.174 | 0.012 | 0.022 |
| 20 | 0.160 | NC | 0.162 | NC | 0.003 |
| 21 | 0.167 | 0.127 | 0.190 | −0.041 | 0.023 |
| 22 | 0.198 | 0.204 | 0.152 | 0.006 | −0.046 |
| Mean | 0.141 | 0.144 | 0.135 | 0.004 | 0.001 |
| Med | 0.145 | 0.120 | 0.135 | 0.009 | 0.004 |
| Min | 0.056 | 0.070 | 0.078 | −0.056 | −0.063 |
| Max | 0.274 | 0.290 | 0.192 | 0.053 | 0.044 |
| SEM | 0.012 | 0.014 | 0.009 | 0.006 | 0.007 |
| 95% CI | 0.025 | 0.030 | 0.018 | 0.013 | 0.015 |
| # of subjects | 20 | 19 | 19 | 19 | 19 |
| Δ % | 2% | −4% | |||
| % of cutaneous tonicity improvement (Ur) | 2% | −4% | |||
| Statistical analysis p = | 0.977 | 0.913 | |||
| Statistical test | T-test | T-test | |||
| % of subjects with an improvement in the cutaneous tonicity (NB: if variation > 0.01) | 47% | 42% | |||